Cited by 139Autoimmune Neurological Disorders and TreatmentsInfectious Encephalopathies and EncephalitisPeripheral Neuropathies and Disorders

Clinical management of pediatric acute-onset neuropsychiatric syndrome: Part II-Use of Immunomodulatory Therapies

Open access
Frankovich, Jennifer, Swedo, Susan, Murphy, Tanya, Dale, Russell C., Agalliu, Dritan, Williams, Kyle, Daines, Michael, Hornig, Mady +22 more·2017·Journal of Child and Adolescent Psychopharmacology

Abstract

Introduction: Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a clinically heterogeneous disorder with a number of different etiologies and disease mechanisms. Inflammatory and postinfectious autoimmune presentations of PANS occur frequently, with some clinical series documenting immune abnormalities in 75%–80% of patients. Thus, comprehensive treatment protocols must include immunological interventions, but their use should be reserved only for PANS cases in which the symptoms represent underlying neuroinflammation or postinfectious autoimmunity, as seen in the PANDAS subgroup (Pediatric Autoimmune Neuropsychiatric Disorders associated with Streptococcal infections). Methods: The PANS Research Consortium (PRC) immunomodulatory task force is comprised of immunologists, rheumatologists, neurologists, infectious disease experts, general pediatricians, psychiatrists, nurse practitioners, and basic scientists with expertise in neuroimmunology and PANS-related animal models. Preliminary treatment guidelines were created in the Spring of 2014 at the National Institute of Health and refined over the ensuing 2 years over conference calls and a shared web-based document. Seven pediatric mental health practitioners, with expertise in diagnosing and monitoring patients with PANS, were consulted to create categories in disease severity and critically review final recommendations. All authors played a role in creating these guidelines. The views of all authors were incorporated and all authors gave final approval of these guidelines. Results: Separate guidelines were created for the use of immunomodulatory therapies in PANS patients with (1) mild, (2) moderate-to-severe, and (3) extreme/life-threatening severity. For mildly impairing PANS, the most appropriate therapy may be “tincture of time” combined with cognitive behavioral therapy and other supportive therapies. If symptoms persist, nonsteroidal anti-inflammatory drugs and/or short oral corticosteroid bursts are recommended. For moderate-to-severe PANS, oral or intravenous corticosteroids may be sufficient. However, intravenous immunoglobulin (IVIG) is often the preferred treatment for these patients by most PRC members. For more severe or chronic presentations, prolonged corticosteroid courses (with taper) or repeated high-dose corticosteroids may be indicated. For PANS with extreme and life-threatening impairment, therapeutic plasma exchange is the first-line therapy given either alone or in combination with IVIG, high-dose intravenous corticosteroids, and/or rituximab. Conclusions: These recommendations will help guide the use of anti-inflammatory and immunomodulatory therapy in the treatment of PANS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/cap.2016.0148

Cites

118 of 118 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Frankovich, J., Swedo, S., Murphy, T., Dale, R. C., Agalliu, D., Williams, K., Daines, M., Hornig, M., Chugani, H., Sanger, T., Muscal, E., Pasternack, M., Cooperstock, M., Gans, H., Zhang, Y., Cunningham, M., Bernstein, G., Bromberg, R., Willett, T., Brown, K., Farhadian, B., Chang, K., Geller, D., Hernandez, J., Sherr, J., Shaw, R., Latimer, E., Leckman, J., Thienemann, M., & PANS/PANDAS Consortium
Affiliations
  • Lucile Packard Children's Hospital (US)
  • National Institutes of Health (US)
  • University of South Florida (US)
  • The University of Sydney (AU)
  • Columbia University (US)
  • Harvard University (US)
  • University of Arizona (US)
  • Columbia University Irving Medical Center (US)
  • Alfred I. duPont Hospital for Children (US)
  • University of Southern California (US)
  • Baylor College of Medicine (US)
  • University of Missouri (US)
  • Stanford Medicine (US)
  • Tufts University (US)
  • University of Oklahoma Health Sciences Center (US)
  • University of Minnesota (US)
  • Pediatric Rheumatology, Miami Rheumatology, LLC, Miami, Florida.
  • Georgetown University Medical Center (US)
  • Yale University (US)
Corresponding author
Frankovich, Jennifer
Venue
Journal of Child and Adolescent Psychopharmacology
Published
2017-09-01
Volume
27
Issue
7
Pages
574-593
ISSN
  • 1044-5463 (ISSN-L)
  • 1557-8992
OpenAlex
W2739465988
Cited by
139
References
118
Citations by year
2026: 20 · 2025: 10 · 2024: 25 · 2023: 18 · 2022: 9 · 2021: 13 · 2020: 10 · 2019: 15 · 2018: 14 · 2017: 5
FWCI
8.38
Type
journal article
Language
en
Open access
Locations
  • Journal of Child and Adolescent Psychopharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Science Foundation
  • Brain and Behavior Research Foundation
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Massachusetts General Hospital
  • American Academy of Child and Adolescent Psychiatry
  • Biogen
  • Teva Pharmaceutical Industries
  • International OCD Foundation
  • F. Hoffmann-La Roche
  • Sunovion
  • Psyadon Pharmaceuticals
  • Neurocrine Biosciences
  • Forest Research Institute
  • University of Oxford
  • Multiple Sclerosis Australia
  • Karolinska Institutet
  • Shire
  • UBS Optimus Foundation
  • Medac
  • National Institutes of Health
  • Centers for Disease Control and Prevention
  • National Health and Medical Research Council
  • National Institute of Mental Health (R21MH087849)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD080096)
Topics
  • Health Sciences › Medicine › Neurology › Autoimmune Neurological Disorders and Treatments
  • Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
  • Health Sciences › Medicine › Neurology › Peripheral Neuropathies and Disorders
Keywords
pediatric acute-onset neuropsychiatric syndrome, PANS, PANDAS, immunomodulatory therapy, corticosteroids, intravenous immunoglobulin, plasma exchange, rituximab, neuroinflammation, treatment guidelines, disease severity classification, cognitive behavioral therapy, nonsteroidal anti-inflammatory drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review